Moexipril-d5
Product Specifications
CAS Number
1356929-49-1
Target
Apoptosis|||Angiotensin-converting Enzyme (ACE)
Related Pathways
Metabolism|||Apoptosis
Bioactivity
Moexipril-d5 intended for use as an internal standard for the quantification of moexipril by GC- or LC-MS. Moexipril is a prodrug form of the angiotensin converting enzyme (ACE) inhibitor moexiprilat. It is converted to moexiprilat in vivo by side chain ester hydrolysis. Moexipril inhibits ACE in a cell-free assay (IC50 = 2.7 µM for the rabbit enzyme) . It also inhibits phosphodiesterase 4 (IC50s = 38, 160, and 230 µM for PDE4B2, PDE4A5 and PDE4D5, respectively) . Moexipril (0.1-30 mg/kg per day) reduces blood pressure in spontaneously hypertensive rats.1 It also reduces infarct volume in a rat model of focal cerebral ischemia when used at a concentration of 0.01 mg/kg.
Smiles
C([C@@H](N[C@@H](CCC1=C(C(=C(C(=C1[2H])[2H])[2H])[2H])[2H])C(OCC)=O)C)(=O)N2CC=3C(C[C@H]2C(O)=O)=CC(OC)=C(OC)C3
Molecular Formula
C27H29D5N2O7
Molecular Weight
503.6
Shipping Conditions
Cool pack
Storage Temperature
-20°C
Product Datasheet
https://www.targetmol.com/attachment/DataSheet/193C1653-0468-4F69-B272-4C18FACFD380/T70883
Curated Selection
Explore Other Products
Discover premium biology products from our extensive collection of 20M+ items
